PURPOSE: Large randomized trials have demonstrated significant survival benefits with the use of adjuvant chemotherapy or chemoradiation therapy for gastric cancer. The importance of adjuvant radiation therapy (RT) remains unclear. We performed an up-to-date meta-analysis of randomized trials testing the use of RT for resectable gastric cancer. METHODS AND MATERIALS: We searched MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials for randomized trials testing adjuvant (including neoadjuvant) RT for resectable gastric cancer. Hazard ratios describing the impact of adjuvant RT on overall survival (OS) and disease-free survival (DFS) were extracted directly from the original studies or calculated from survival curves. Pooled estimates were obtained using the inverse variance method. Subgroup analyses were performed to determine whether the efficacy of RT varies with chemotherapy use, RT timing, geographic region, type of nodal dissection performed, or lymph node status. RESULTS: Thirteen studies met all inclusion criteria and were used for this analysis. Adjuvant RT was associated with a significant improvement in both OS (HR = 0.78, 95% CI: 0.70-0.86, P<.001) and DFS (HR = 0.71, 95% CI: 0.63-0.80, P<.001). In the 5 studies that tested adjuvant chemoradiation therapy against adjuvant chemotherapy, similar effects were seen for OS (HR = 0.83, 95% CI: 0.67-1.03, P=.087) and DFS (HR = 0.77, 95% CI: 0.91-0.65, P=.002). Available data did not reveal any subgroup of patients that does not benefit from adjuvant RT. CONCLUSION: In randomized trials for resectable gastric cancer, adjuvant RT provides an approximately 20% improvement in both DFS and OS. Available data do not reveal a subgroup of patients that does not benefit from adjuvant RT. Further study is required to optimize the implementation of adjuvant RT for gastric cancer with regard to patient selection and integration with systemic therapy.
PURPOSE: Large randomized trials have demonstrated significant survival benefits with the use of adjuvant chemotherapy or chemoradiation therapy for gastric cancer. The importance of adjuvant radiation therapy (RT) remains unclear. We performed an up-to-date meta-analysis of randomized trials testing the use of RT for resectable gastric cancer. METHODS AND MATERIALS: We searched MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials for randomized trials testing adjuvant (including neoadjuvant) RT for resectable gastric cancer. Hazard ratios describing the impact of adjuvant RT on overall survival (OS) and disease-free survival (DFS) were extracted directly from the original studies or calculated from survival curves. Pooled estimates were obtained using the inverse variance method. Subgroup analyses were performed to determine whether the efficacy of RT varies with chemotherapy use, RT timing, geographic region, type of nodal dissection performed, or lymph node status. RESULTS: Thirteen studies met all inclusion criteria and were used for this analysis. Adjuvant RT was associated with a significant improvement in both OS (HR = 0.78, 95% CI: 0.70-0.86, P<.001) and DFS (HR = 0.71, 95% CI: 0.63-0.80, P<.001). In the 5 studies that tested adjuvant chemoradiation therapy against adjuvant chemotherapy, similar effects were seen for OS (HR = 0.83, 95% CI: 0.67-1.03, P=.087) and DFS (HR = 0.77, 95% CI: 0.91-0.65, P=.002). Available data did not reveal any subgroup of patients that does not benefit from adjuvant RT. CONCLUSION: In randomized trials for resectable gastric cancer, adjuvant RT provides an approximately 20% improvement in both DFS and OS. Available data do not reveal a subgroup of patients that does not benefit from adjuvant RT. Further study is required to optimize the implementation of adjuvant RT for gastric cancer with regard to patient selection and integration with systemic therapy.
Authors: Vincenzo Valentini; Francesco Cellini; Bruce D Minsky; Gian Carlo Mattiucci; Mario Balducci; Giuseppe D'Agostino; Elisa D'Angelo; Nicola Dinapoli; Nicola Nicolotti; Chiara Valentini; Giuseppe La Torre Journal: Radiother Oncol Date: 2009-07-06 Impact factor: 6.280
Authors: Twisha Chakravarty; Christopher H Crane; Jaffer A Ajani; Paul F Mansfield; Tina M Briere; A Sam Beddar; Henry Mok; Valerie K Reed; Sunil Krishnan; Marc E Delclos; Prajnan Das Journal: Int J Radiat Oncol Biol Phys Date: 2011-12-02 Impact factor: 7.038
Authors: Stefan Michiels; Pascal Piedbois; Sarah Burdett; Nathalie Syz; Lesley Stewart; Jean-Pierre Pignon Journal: Int J Technol Assess Health Care Date: 2005 Impact factor: 2.188
Authors: Pamela L Kunz; Matthew Gubens; George A Fisher; James M Ford; Daphne Y Lichtensztajn; Christina A Clarke Journal: J Clin Oncol Date: 2012-09-04 Impact factor: 44.544
Authors: Stefan Haneder; Johannes Michael Budjan; Stefan Oswald Schoenberg; Simon Konstandin; Lothar Rudi Schad; Ralf Dieter Hofheinz; Veronika Gramlich; Frederik Wenz; Frank Lohr; Judit Boda-Heggemann Journal: Strahlenther Onkol Date: 2014-12-02 Impact factor: 3.621